← FDA DRUG APPROVALS

FDA ANDA · ANDA206384

RALOXIFENE HYDROCHLORIDE

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA206384
TYPE
ANDA
ORIGINAL APPROVAL
2016-10-12
LATEST ACTION
2019-08-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

RALOXIFENE HYDROCHLORIDEPrescription
RALOXIFENE HYDROCHLORIDE 60MG · TABLET · ORAL

Approval history

2019-08-23Labeling · Supplement 4 · standardAP
2016-10-12UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →